OBJECTIVES: The purpose of this study was to evaluate the mechanisms for improved exercise capacity after endurance exercise training (ET) in elderly patients with heart failure and preserved ejection fraction (HFPEF). BACKGROUND: Exercise intolerance, measured objectively by reduced peak oxygen consumption (VO(2)), is the primary chronic symptom in HFPEF and is improved by ET. However, the mechanisms are unknown. METHODS: Forty stable, compensated HFPEF outpatients (mean age 69 ± 6 years) were examined at baseline and after 4 months of ET (n = 22) or attention control (n = 18). The VO(2) and its determinants were assessed during rest and peak upright cycle exercise. RESULTS: After ET, peak VO(2) in those patients was higher than in control patients (16.3 ± 2.6 ml/kg/min vs. 13.1 ± 3.4 ml/kg/min; p = 0.002). That was associated with higher peak heart rate (139 ± 16 beats/min vs. 131 ± 20 beats/min; p = 0.03), but no difference in peak end-diastolic volume (77 ± 18 ml vs. 77 ± 17 ml; p = 0.51), stroke volume (48 ± 9 ml vs. 46 ± 9 ml; p = 0.83), or cardiac output (6.6 ± 1.3 l/min vs. 5.9 ± 1.5 l/min; p = 0.32). However, estimated peak arterial-venous oxygen difference was significantly higher in ET patients (19.8 ± 4.0 ml/dl vs. 17.3 ± 3.7 ml/dl; p = 0.03). The effect of ET on cardiac output was responsible for only 16% of the improvement in peak VO(2). CONCLUSIONS: In elderly stable compensated HFPEF patients, peak arterial-venous oxygen difference was higher after ET and was the primary contributor to improved peak VO(2). This finding suggests that peripheral mechanisms (improved microvascular and/or skeletal muscle function) contribute to the improved exercise capacity after ET in HFPEF. (Prospective Aerobic Reconditioning Intervention Study [PARIS]; NCT01113840).
OBJECTIVES: The purpose of this study was to evaluate the mechanisms for improved exercise capacity after endurance exercise training (ET) in elderly patients with heart failure and preserved ejection fraction (HFPEF). BACKGROUND: Exercise intolerance, measured objectively by reduced peak oxygen consumption (VO(2)), is the primary chronic symptom in HFPEF and is improved by ET. However, the mechanisms are unknown. METHODS: Forty stable, compensated HFPEF outpatients (mean age 69 ± 6 years) were examined at baseline and after 4 months of ET (n = 22) or attention control (n = 18). The VO(2) and its determinants were assessed during rest and peak upright cycle exercise. RESULTS: After ET, peak VO(2) in those patients was higher than in control patients (16.3 ± 2.6 ml/kg/min vs. 13.1 ± 3.4 ml/kg/min; p = 0.002). That was associated with higher peak heart rate (139 ± 16 beats/min vs. 131 ± 20 beats/min; p = 0.03), but no difference in peak end-diastolic volume (77 ± 18 ml vs. 77 ± 17 ml; p = 0.51), stroke volume (48 ± 9 ml vs. 46 ± 9 ml; p = 0.83), or cardiac output (6.6 ± 1.3 l/min vs. 5.9 ± 1.5 l/min; p = 0.32). However, estimated peak arterial-venous oxygen difference was significantly higher in ET patients (19.8 ± 4.0 ml/dl vs. 17.3 ± 3.7 ml/dl; p = 0.03). The effect of ET on cardiac output was responsible for only 16% of the improvement in peak VO(2). CONCLUSIONS: In elderly stable compensated HFPEF patients, peak arterial-venous oxygen difference was higher after ET and was the primary contributor to improved peak VO(2). This finding suggests that peripheral mechanisms (improved microvascular and/or skeletal muscle function) contribute to the improved exercise capacity after ET in HFPEF. (Prospective Aerobic Reconditioning Intervention Study [PARIS]; NCT01113840).
Authors: Mark Haykowsky; Jonathan McGavock; Isabelle Vonder Muhll; Matthew Koller; Sandra Mandic; Robert Welsh; Dylan Taylor Journal: J Gerontol A Biol Sci Med Sci Date: 2005-03 Impact factor: 6.053
Authors: Mark J Haykowsky; Peter H Brubaker; Jerry M John; Kathryn P Stewart; Timothy M Morgan; Dalane W Kitzman Journal: J Am Coll Cardiol Date: 2011-07-12 Impact factor: 24.094
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: S J Keteyian; A B Levine; C A Brawner; T Kataoka; F J Rogers; J R Schairer; P D Stein; T B Levine; S Goldstein Journal: Ann Intern Med Date: 1996-06-15 Impact factor: 25.391
Authors: Whitney E Hornsby; Mohamed-Ali Sareini; Jessica R Golbus; Cristen J Willer; Jennifer L McNamara; Matthew C Konerman; Scott L Hummel Journal: J Card Fail Date: 2018-09-13 Impact factor: 5.712
Authors: Kilian Weiss; Michael Schär; Gurusher S Panjrath; Yi Zhang; Kavita Sharma; Paul A Bottomley; Asieh Golozar; Angela Steinberg; Gary Gerstenblith; Stuart D Russell; Robert G Weiss Journal: Circ Heart Fail Date: 2017-07 Impact factor: 8.790
Authors: Andrew J Stewart Coats; Daniel E Forman; Mark Haykowsky; Dalane W Kitzman; Amy McNeil; Tavis S Campbell; Ross Arena Journal: Nat Rev Cardiol Date: 2017-05-18 Impact factor: 32.419
Authors: Benjamin W Van Tassell; Cory R Trankle; Justin M Canada; Salvatore Carbone; Leo Buckley; Dinesh Kadariya; Marco G Del Buono; Hayley Billingsley; George Wohlford; Michele Viscusi; Claudia Oddi-Erdle; Nayef A Abouzaki; Dave Dixon; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate Journal: Circ Heart Fail Date: 2018-08 Impact factor: 8.790
Authors: Mark J Haykowsky; Peter H Brubaker; Timothy M Morgan; Stephen Kritchevsky; Joel Eggebeen; Dalane W Kitzman Journal: J Gerontol A Biol Sci Med Sci Date: 2013-03-22 Impact factor: 6.053
Authors: Dalane W Kitzman; Barbara Nicklas; William E Kraus; Mary F Lyles; Joel Eggebeen; Timothy M Morgan; Mark Haykowsky Journal: Am J Physiol Heart Circ Physiol Date: 2014-03-21 Impact factor: 4.733